Colleges
Research groups
Jack Tan
DPhil, BSc (Hons)
Senior Postdoctoral Scientist
I am a EPA Cephalosporin Early Research and Teaching Fellow at St Edmund Hall. I am a postdoctoral scientist in Alain Townsend lab at the Weatherall Institute of Molecular Medicine on developing next generation nanoparticle vaccines mainly against infectious diseases. I am currently a Project Manager and Senior Postdoctoral Scientist on a CEPI-funded project involving the development of a pan-sarbecovirus (SARS-like betacoronaviruses) vaccine. I am also trying to understand the antibody responses post infection or vaccination to help design better vaccines.
Key publications
-
A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses.
Journal article
Tan TK. et al, (2021), Nat Commun, 12
Recent publications
-
Hepcidin-Mediated Hypoferremia Disrupts Immune Responses to Vaccination and Infection.
Journal article
Frost JN. et al, (2021), Med (N Y), 2, 164 - 179.e12
-
A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses.
Journal article
Tan TK. et al, (2021), Nat Commun, 12
-
Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.
Journal article
Huo J. et al, (2020), Nat Struct Mol Biol, 27
-
Overcoming Symmetry Mismatch in Vaccine Nanoassembly through Spontaneous Amidation
Journal article
Rahikainen R. et al, (2020), Angewandte Chemie
-
Micro-fusion inhibition tests: quantifying antibody neutralization of virus-mediated cell-cell fusion.
Journal article
Thakur N. et al, (2020), J Gen Virol
-
Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.
Journal article
Huo J. et al, (2020), Cell Host Microbe, 28
-
Overcoming Symmetry Mismatch in Vaccine Nanoassembly via Spontaneous Amidation.
Journal article
Howarth M. et al, (2020), Angew Chem Int Ed Engl
-
Lung-targeting lentiviral vector for passive immunisation against influenza
Journal article
TAN TK. et al, (2020), Thorax
-
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient.
Journal article
Zhou D. et al, (2020), Nat Struct Mol Biol
-
Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.
Journal article
Huo J. et al, (2020), Nat Struct Mol Biol
-
Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.
Journal article
Huo J. et al, (2020), Cell Host Microbe
-
Lung targeting lentiviral vector for passive immunisation against influenza
Working paper
TAN T. et al, (2020)
-
Lentiviral-Mediated Expression of Monoclonal Antibodies in the Lung to Protect Against Influenza
Conference paper
Du Y. et al, (2020), MOLECULAR THERAPY, 28, 60 - 60
-
An improved method for the rescue of recombinant Newcastle disease virus.
Journal article
Cheow P-S. et al, (2020), Biotechniques, 68, 96 - 100
-
Broadly Inhibiting Antineuraminidase Monoclonal Antibodies Induced by Trivalent Influenza Vaccine and H7N9 Infection in Humans.
Journal article
Rijal P. et al, (2020), J Virol, 94
-
cGAMP loading enhances the immunogenicity of VLP vaccines
Journal article
Chauveau L. et al, (2020)
-
A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy.
Journal article
Miao X. et al, (2020), MAbs, 12
-
Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases
Conference paper
De Caneva A. et al, (2018), HUMAN GENE THERAPY, 29, A115 - A115
-
Lung-targeted lentiviral vector mediates passive immunisation against influenza
Conference paper
Tan TK. et al, (2018), HUMAN GENE THERAPY, 29, A119 - A119
-
Use of Pseudotyped, Replication-Deficient Influenza to Facilitate Testing of Gene Delivery Strategies for Treatment of Highly Infectious Diseases
Conference paper
Tan TK. et al, (2018), MOLECULAR THERAPY, 26, 242 - 243